After AR-105 VAP Failure, Aridis Looks To AR-301 For Value Justification
Executive Summary
Aridis is effectively pulling the plug on AR-105 after the mAb failed in a Phase II ventilator-associated pneumonia trial. It will now focus on its remaining pipeline, led by Phase III asset AR-301.